|
|
|
|
|
|
Sponsored by: |
Novartis |
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00417820 |
The purpose of this study is to assess the local tolerability of a single topical administration of BCT194 in healthy volunteers and, potentially, to evaluate the safety, tolerability, and efficacy of a multiple topical administrations in patients with psoriasis.
Condition | Intervention | Phase |
Psoriasis |
Drug: BCT194 |
Phase I |
MedlinePlus related topics: | Psoriasis |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Multicenter, Double-Blind, Placebo Controlled Exploratory Study to Evaluate the Safety, Tolerability and Pharmacodynamics of a Single Administration of BCT194 in Healthy Volunteers and Multiple Administrations in Patients With Psoriasis. |
Estimated Enrollment: | 35 |
Study Start Date: | November 2006 |
Study Completion Date: | November 2007 |
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
All participants:
Male subjects must be using a double-barrier local contraception.
Psoriasis patients:
Exclusion Criteria:
All participants:
History of:
Psoriasis patients:
Other protocol-defined inclusion/exclusion criteria may apply
Study ID Numbers: | CBCT194A2101 |
First Received: | January 3, 2007 |
Last Updated: | November 28, 2007 |
ClinicalTrials.gov Identifier: | NCT00417820 |
Health Authority: | Austria: Agency for Health and Food Safety |
|
|